Log In
BCIQ
Print this Print this
 

ASN200

  Manage Alerts
Collapse Summary General Information
Company Arsanis Inc.
DescriptionCombination of two monoclonal antibodies (mAbs)
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationEscherichia
Indication DetailsTreat multidrug-resistant E. coli infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today